Dysregulated immune proteins in plasma in the UK Biobank predict Multiple Myeloma 12 years before clinical diagnosis.
Fieggen J. et al, (2025), Blood Adv
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Perrot A. et al, (2025), J Clin Oncol, 43
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach.
Kannan A. et al, (2025), Blood Rev
Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper.
Pinney J. et al, (2025), Br J Haematol
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar R. et al, (2025), Indian Journal of Hematology and Blood Transfusion
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Ramasamy K. et al, (2024), Clin Lymphoma Myeloma Leuk
The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service.
Popat R. et al, (2024), EJHaem, 5, 1133 - 1143
Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
Hungria V. et al, (2024), Cancers, 16
Challenges in designing and running smouldering myeloma interventional clinical trials.
Lecat C. et al, (2024), EJHaem, 5, 418 - 420
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
Hughes D. et al, (2024), Br J Haematol
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.
Agarwal G. et al, (2024), Haematologica
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Leleu X. et al, (2024), Future Oncol
A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
Ansari-Pour N. et al, (2024), BLOOD, 144, 1909 - 1910
Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma
Gooding S. et al, (2024), BLOOD, 144, 6848 - 6849
Increased Rates of MRD Conversion from Positive ( plus ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial
Bygrave C. et al, (2024), BLOOD, 144, 4745 - 4745